1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Traaseth, N.J. Shi, L. Verardi, R. Veglia, G. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 106 10165 10170 10.1073/pnas.0904290106 19509339 Structure and topology of monomeric phospholamban in lipid membranes determined by a hybrid solution and solid-state NMR approach. 2009 NE J.Biomol.Nmr JBNME9 0800 0925-2738 44 195 205 10.1007/s10858-009-9328-9 19597943 A refinement protocol to determine structure, topology, and depth of insertion of membrane proteins using hybrid solution and solid-state NMR restraints. 2009 10.2210/pdb2kb7/pdb pdb_00002kb7 6150.477 Phospholamban 1 man polymer no no AMEKVQYLTRSAIRRASTIEMPQQARQNLQNLFINFALILIFLLLIAIIVMLL AMEKVQYLTRSAIRRASTIEMPQQARQNLQNLFINFALILIFLLLIAIIVMLL P polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n Bl21de3phi sample pln 562 Escherichia coli 562 Escherichia coli plasmid pMAL database_2 pdbx_nmr_software pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Data collection Database references Derived calculations 1 0 2009-06-16 1 1 2011-07-13 1 2 2022-03-16 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name Solution NMR structure of monomeric phospholamban BMRB Y RCSB 2008-11-21 REL REL structures with the least restraint violations 200 20 2D 1H-15N HSQC 3D H(CCO)NH 3D C(CO)NH 3D 1H-15N NOESY 2D [1H,15N] PISEMA 2D [1H,15N]SAMPI4 1.5 mM [U-99% 15N] and [U-99% 13C; U-99% 15N] % [U-99% 15N] and [15N-Ala] and [15N-Arg] and [15N-Asn] and [15N-Ile] and [15N-Met] and [15N-Leu] and [15N-Phe] and [15N-Val] and [15N-Ser] and [15N-Gln26,Gln29] 6.0 ambient K Authors state that they define the z-axis to be parallel with the bilayer normal. Also, the origin (or in other words, when the z Cartesian coordinate is 0) is defined to be the center of the lipid bilayer. simulated annealing 1 fewest violations 1.5 mM [U-99% 15N] and [U-99% 13C; U-99% 15N] Phospholamban, 90% H2O/10% D2O 90% H2O/10% D2O 160/1 lipid/protein (mol/mol) [U-99% 15N] and [15N-Ala] and [15N-Arg] and [15N-Asn] and [15N-Ile] and [15N-Met] and [15N-Leu] and [15N-Phe] and [15N-Val] and [15N-Ser] and [15N-Gln26,Gln29] Phospholamban, 100% H2O 100% H2O Schwieters, C. et al. refinement X-PLOR NIH 2.18 Schwieters, C. et al. data analysis X-PLOR NIH 2.18 Schwieters, C. et al. structure solution X-PLOR NIH 2.18 600 Varian VNMRS Varian VNMRS 700 Varian VNMRS Varian VNMRS 600 Bruker DMX Bruker DMX ALA 1 n 1 ALA 1 P MET 2 n 2 MET 2 P GLU 3 n 3 GLU 3 P LYS 4 n 4 LYS 4 P VAL 5 n 5 VAL 5 P GLN 6 n 6 GLN 6 P TYR 7 n 7 TYR 7 P LEU 8 n 8 LEU 8 P THR 9 n 9 THR 9 P ARG 10 n 10 ARG 10 P SER 11 n 11 SER 11 P ALA 12 n 12 ALA 12 P ILE 13 n 13 ILE 13 P ARG 14 n 14 ARG 14 P ARG 15 n 15 ARG 15 P ALA 16 n 16 ALA 16 P SER 17 n 17 SER 17 P THR 18 n 18 THR 18 P ILE 19 n 19 ILE 19 P GLU 20 n 20 GLU 20 P MET 21 n 21 MET 21 P PRO 22 n 22 PRO 22 P GLN 23 n 23 GLN 23 P GLN 24 n 24 GLN 24 P ALA 25 n 25 ALA 25 P ARG 26 n 26 ARG 26 P GLN 27 n 27 GLN 27 P ASN 28 n 28 ASN 28 P LEU 29 n 29 LEU 29 P GLN 30 n 30 GLN 30 P ASN 31 n 31 ASN 31 P LEU 32 n 32 LEU 32 P PHE 33 n 33 PHE 33 P ILE 34 n 34 ILE 34 P ASN 35 n 35 ASN 35 P PHE 36 n 36 PHE 36 P ALA 37 n 37 ALA 37 P LEU 38 n 38 LEU 38 P ILE 39 n 39 ILE 39 P LEU 40 n 40 LEU 40 P ILE 41 n 41 ILE 41 P PHE 42 n 42 PHE 42 P LEU 43 n 43 LEU 43 P LEU 44 n 44 LEU 44 P LEU 45 n 45 LEU 45 P ILE 46 n 46 ILE 46 P ALA 47 n 47 ALA 47 P ILE 48 n 48 ILE 48 P ILE 49 n 49 ILE 49 P VAL 50 n 50 VAL 50 P MET 51 n 51 MET 51 P LEU 52 n 52 LEU 52 P LEU 53 n 53 LEU 53 P author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 P P O H LEU PHE 32 36 1.59 2 P P O H ALA ILE 37 41 1.55 3 P P O H SER ARG 11 15 1.57 3 P P O H ALA ILE 37 41 1.60 6 P P O H LEU PHE 32 36 1.56 6 P P O H ARG SER 14 17 1.58 7 P P O H LEU PHE 32 36 1.60 11 P P HD22 HD22 ASN ASN 31 35 1.31 14 P P H3 H ALA MET 1 2 1.32 15 P P O H ALA ILE 37 41 1.60 16 P P O H SER ARG 11 15 1.58 18 P P O H LEU PHE 32 36 1.58 1 P LYS 4 55.44 -3.68 1 P ILE 19 -34.78 -28.21 2 P PRO 22 -30.07 129.75 3 P PRO 22 -27.35 131.63 3 P ARG 26 -62.84 -74.68 4 P MET 21 -90.75 -71.11 4 P PRO 22 -66.71 -87.46 4 P GLN 23 -155.67 -79.24 4 P GLN 24 -62.96 0.27 5 P MET 21 -99.42 -69.53 5 P PRO 22 -64.39 -85.50 5 P GLN 23 -155.43 -82.11 5 P GLN 24 -69.22 8.87 6 P ARG 15 -41.18 -19.00 6 P SER 17 -76.15 -81.55 6 P GLU 20 -177.83 -124.59 6 P MET 21 -160.49 -53.87 6 P PRO 22 -97.07 -76.43 6 P GLN 23 -127.39 -133.29 7 P LYS 4 53.56 -0.99 7 P ILE 19 -35.40 -27.63 8 P MET 2 -87.46 -94.34 8 P ILE 19 -34.76 -28.30 9 P ILE 19 -37.43 -30.33 9 P PRO 22 -37.70 124.73 10 P ILE 19 -43.14 -19.16 10 P GLU 20 -133.09 -65.26 10 P MET 21 -175.75 113.09 11 P ILE 19 -36.05 -28.83 11 P PRO 22 -98.27 -98.49 11 P GLN 23 -158.46 -17.63 12 P MET 2 -32.84 -34.83 12 P ILE 19 -37.09 -23.84 12 P GLU 20 -146.59 -57.50 12 P MET 21 178.98 117.77 13 P SER 17 -72.52 -77.65 13 P ILE 19 3.81 115.40 13 P GLU 20 4.89 94.64 13 P GLN 23 -163.68 -34.38 14 P PRO 22 -36.97 124.11 14 P ARG 26 -65.42 -76.90 15 P ILE 19 -35.95 -29.53 15 P PRO 22 -39.89 125.25 16 P ARG 26 -64.94 -75.00 17 P ILE 19 4.24 112.41 17 P GLU 20 -20.51 82.07 17 P GLN 23 -159.87 -43.56 18 P ILE 19 2.37 114.58 18 P GLU 20 -1.02 92.13 18 P PRO 22 -44.75 -70.98 18 P GLN 23 -166.32 -25.42 19 P ILE 19 -38.91 -26.83 19 P PRO 22 -38.58 122.81 20 P ILE 19 3.18 110.93 20 P GLU 20 2.57 -100.13 20 P MET 21 2.08 75.01 20 P GLN 23 -156.73 -26.31 20 P GLN 24 -104.61 -71.97 Y Hybrid solution and solid-state NMR structure of monomeric phospholamban in lipid bilayers 1 N N P LYS 4 A LYS 4 HELX_P P ILE 19 A ILE 19 1 1 16 P GLN 24 A GLN 24 HELX_P P LEU 53 A LEU 53 1 2 30 MEMBRANE PROTEIN phospholamban, PISEMA, hybrid method, lipid bilayers, topology, MEMBRANE PROTEIN 2KB7 PDB 1 2KB7 1 53 2KB7 1 53 2KB7 P 1 1 53